Who are Tocilizumab plus methotrexate's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tocilizumab-plus-methotrexate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Tocilizumab plus methotrexate — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tocilizumab plus methotrexate (Tocilizumab plus methotrexate) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IL-6 receptor antagonist + DMARD combination. Area: Immunology.

marketed IL-6 receptor antagonist + DMARD combination IL-6 receptor (tocilizumab); dihydrofolate reductase (methotrexate) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Tocilizumab plus methotrexate (Tocilizumab plus methotrexate) — SURPRISE Study Group. Tocilizumab blocks IL-6 receptor signaling to reduce inflammation, while methotrexate inhibits dihydrofolate reductase to suppress immune cell proliferation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tocilizumab plus methotrexate TARGET	Tocilizumab plus methotrexate	SURPRISE Study Group	marketed	IL-6 receptor antagonist + DMARD combination	IL-6 receptor (tocilizumab); dihydrofolate reductase (methotrexate)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IL-6 receptor antagonist + DMARD combination class)

SURPRISE Study Group · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tocilizumab plus methotrexate — Competitive Intelligence Brief. https://druglandscape.com/ci/tocilizumab-plus-methotrexate. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing